<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Roche</title>
	<atom:link href="http://www.tapanray.in/tag/roche/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Patents, Patients and Prices Collide</title>
		<link>http://www.tapanray.in/when-patents-patients-and-prices-collide/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-patents-patients-and-prices-collide</link>
		<comments>http://www.tapanray.in/when-patents-patients-and-prices-collide/#comments</comments>
		<pubDate>Sun, 19 Oct 2025 12:39:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[atrophy]]></category>
		<category><![CDATA[Collide]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Evrysdi]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[muscular]]></category>
		<category><![CDATA[Natco Pharma]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Risdiplam]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[spinal]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10982</guid>
		<description><![CDATA[Supreme Court Clears Natco to Launch Low-Cost Version of Roche’s Spinal Drug in India: A Judgment That Redefines Access and Innovation in India’s Pharma Landscape. The Supreme Court of India has just recently refused to interfere with the Delhi High &#8230; <a href="http://www.tapanray.in/when-patents-patients-and-prices-collide/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-patents-patients-and-prices-collide/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gamification in Pharma: Creates Engaging Patient Experience For Better Results</title>
		<link>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gamification-in-pharma-creates-engaging-patient-experience-for-better-results</link>
		<comments>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/#comments</comments>
		<pubDate>Mon, 21 Jan 2019 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Autism]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[better]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[engaging]]></category>
		<category><![CDATA[EVO]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[gamification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[motivate]]></category>
		<category><![CDATA[mySugr]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9373</guid>
		<description><![CDATA[On January 03, 2019, media reports flashed &#8211; “A video game-based ‘digital medicine’ tool can help reduce symptoms in children with autism spectrum disorder (ASD) and attention/deficit-hyperactivity disorder (ADHD).” This study was published in the Journal of Autism and Developmental Disorders, confirming &#8230; <a href="http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gamification-in-pharma-creates-engaging-patient-experience-for-better-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Providing Unique Patient Experience &#8211; A New Brand Differentiator</title>
		<link>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=providing-unique-patient-experience-a-new-brand-differentiator</link>
		<comments>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/#comments</comments>
		<pubDate>Sun, 04 Mar 2018 23:50:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AR]]></category>
		<category><![CDATA[Augmented]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[differentiator]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Flatiron]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet of Things]]></category>
		<category><![CDATA[IoT]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Virtual reality]]></category>
		<category><![CDATA[VR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8887</guid>
		<description><![CDATA[“Pharma industry, including the patients in India are so different from other countries. Thus, any strategic shift from conventional pharma brand marketing approach &#8211; going beyond doctors, won’t be necessary.” The above mindset is interesting and may well hold good &#8230; <a href="http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/providing-unique-patient-experience-a-new-brand-differentiator/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Core Purpose of Pharma Business Much Beyond Profit Making?</title>
		<link>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-core-purpose-of-pharma-business-much-beyond-profit-making</link>
		<comments>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/#comments</comments>
		<pubDate>Mon, 10 Nov 2014 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carmakers]]></category>
		<category><![CDATA[Chan]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[expenditure. India]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[margins]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Oil&gas]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pupose]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[West]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6164</guid>
		<description><![CDATA[Dr. Margaret Chan, the Director General of the World Health Organization (WHO), at a briefing to discuss the Ebola outbreak in West Africa at the UN Foundation in Washington on September 3, 2014 said: “Big Pharma&#8217;s greed for profits, not &#8230; <a href="http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Kickbacks And Bribes Oil Every Part of India’s Healthcare Machinery” &#8211; A National Shame?</title>
		<link>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame</link>
		<comments>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/#comments</comments>
		<pubDate>Mon, 07 Jul 2014 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bribes]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[Desai]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Ketan]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Lucentis]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Nundy]]></category>
		<category><![CDATA[Parilamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Samiran]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5584</guid>
		<description><![CDATA[“Corruption ruins the doctor-patient relationship in India” - highlights an article published in the well-reputed British Medical Journal (BMJ) on 08 May 2014. The author David Berger wrote, “Kickbacks and bribes oil every part of the country’s healthcare machinery and &#8230; <a href="http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moving Up The Generic Pharma Value Chain</title>
		<link>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=moving-up-the-generic-pharma-value-chain</link>
		<comments>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/#comments</comments>
		<pubDate>Mon, 30 Jun 2014 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[BIPP]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fondaparinux]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlobaData]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[moving]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Ohm]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[SBIRI]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Valcyte]]></category>
		<category><![CDATA[valsartan]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5565</guid>
		<description><![CDATA[June 2014 underscores a significant development for the generic drug exporters of India. Much-delayed and highly expected launch of generic Diovan (Valsartan) is now on its way, as Ranbaxy has reportedly received US-FDA approval to launch the first generic version of this blood pressure drug &#8230; <a href="http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/moving-up-the-generic-pharma-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
